Pharmacokinetic studies with recombinant hirudin in dogs
Research article published in Folia haematologica (Leipzig, Germany : 1928) (1988)
Abstract
The knowledge of the pharmacokinetics of recombinant hirudin is essential for potential clinical use of this selective thrombin inhibitor. For detailed information about absorption, distribution and elimination, pharmacokinetic studies with recombinant hirudin were carried out in dogs. The plasma concentration time curve after intravenous injection could be best described by an open two-compartment model with first order kinetics. The subcutaneous application of recombinant hirudin produced anticoagulantly effective blood level for a prolonged period of time. Recombinant hirudin is distributed into the extracellular space. This is also found in nephrectomized dogs. Recombinant hirudin is eliminated through the kidneys by glomerular filtration in active form with a half-life of 72 minutes.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Pharmacokinetic studies of recombinant hirudin in dogs showed intravenous kinetics fitting an open two-compartment model, distribution into extracellular space, renal elimination in active form by glomerular filtration, and prolonged anticoagulantly effective blood levels after subcutaneous dosing.
Why This Matters for Hirudotherapy
This study examined the pharmacokinetics of recombinant hirudin — a selective thrombin inhibitor derived from the medicinal leech anticoagulant — in dogs, characterizing its absorption, distribution, and elimination after intravenous and subcutaneous administration. The investigators found that intravenous injection followed an open two-compartment model with first-order kinetics, subcutaneous administration produced prolonged anticoagulantly effective blood levels, and the drug was eliminated renally via glomerular filtration in active form with a half-life of 72 minutes. For ASH and hirudotherapy, this work is directly relevant because hirudin is a cornerstone leech-secretome anticoagulant, and understanding its disposition helps inform dosing and safety considerations for leech-derived anticoagulant therapies. However, the chief limitation is that these are canine pharmacokinetic data, not human results, so the findings cannot be directly extrapolated to clinical hirudotherapy or human dosing without further study.
Citation
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026